Research and progress of focused ultrasound in the treatment of Alzheimer ’s disease
This article reviews the application research and progress of focused ultrasound in the treatment of Alzheimer’s disease, in order to provide new directions and ideas for the treatment of Alzheimer’s disease. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - December 21, 2023 Category: Neurology Source Type: research
A Series Of Biguanide Ligands and Their Cu(II) Complexes: Cholinesterase Inhibitory And Antimicrobial Properties
Chem Biodivers. 2023 Dec 15:e202301434. doi: 10.1002/cbdv.202301434. Online ahead of print.ABSTRACTIn this work, a series of biguanide hydrochloride salts and their Cu(II) complexes were synthesized and screened for their acetyl/butyryl choline esterase inhibitory and antimicrobial properties. The structures of the synthesized compounds were characterised by common spectroscopic and analytical methods. Biguanide compounds showed considerably lower inhibitory activity compared to the reference drugs donepezil and galantamine. On the other hand, complexation of the biguanide compounds with Cu(II) resulted in dramatic increas...
Source: Chemistry and Biodiversity - December 15, 2023 Category: Biochemistry Authors: Julide Nacaroglu Ozge Gungor Muhammet Kose Source Type: research
A Series Of Biguanide Ligands and Their Cu(II) Complexes: Cholinesterase Inhibitory And Antimicrobial Properties
Chem Biodivers. 2023 Dec 15:e202301434. doi: 10.1002/cbdv.202301434. Online ahead of print.ABSTRACTIn this work, a series of biguanide hydrochloride salts and their Cu(II) complexes were synthesized and screened for their acetyl/butyryl choline esterase inhibitory and antimicrobial properties. The structures of the synthesized compounds were characterised by common spectroscopic and analytical methods. Biguanide compounds showed considerably lower inhibitory activity compared to the reference drugs donepezil and galantamine. On the other hand, complexation of the biguanide compounds with Cu(II) resulted in dramatic increas...
Source: Chemistry and Biodiversity - December 15, 2023 Category: Biochemistry Authors: Julide Nacaroglu Ozge Gungor Muhammet Kose Source Type: research
A Series Of Biguanide Ligands and Their Cu(II) Complexes: Cholinesterase Inhibitory And Antimicrobial Properties
Chem Biodivers. 2023 Dec 15:e202301434. doi: 10.1002/cbdv.202301434. Online ahead of print.ABSTRACTIn this work, a series of biguanide hydrochloride salts and their Cu(II) complexes were synthesized and screened for their acetyl/butyryl choline esterase inhibitory and antimicrobial properties. The structures of the synthesized compounds were characterised by common spectroscopic and analytical methods. Biguanide compounds showed considerably lower inhibitory activity compared to the reference drugs donepezil and galantamine. On the other hand, complexation of the biguanide compounds with Cu(II) resulted in dramatic increas...
Source: Chemistry and Biodiversity - December 15, 2023 Category: Biochemistry Authors: Julide Nacaroglu Ozge Gungor Muhammet Kose Source Type: research
Nanoplasmonic biosensors for multicolor visual analysis of acetylcholinesterase activity and drug inhibitor screening in point-of-care testing
Biosens Bioelectron. 2023 Dec 8;247:115912. doi: 10.1016/j.bios.2023.115912. Online ahead of print.ABSTRACTThe monitoring of acetylcholinesterase (AChE) activity and the screening of its inhibitors are significance of the diagnosis and drug therapy of nervous diseases. A metal ions-mediated signal amplification strategy was developed for the highly sensitive and multicolor assay of AChE activity and visually screening its drug inhibitors. After the specific reaction between AChE and acetylthiocholine (ATCh), the hydrolysis product thiocholine (TCh) can directly and decompose the α-FeOOH nanorods (NRs) to release amounts o...
Source: Biosensors and Bioelectronics - December 14, 2023 Category: Biotechnology Authors: De Yan Li Lu Chen Cai Yan Li Jin Zhang Yan Zhao Yun Hui Yang Tong Yang Source Type: research
Nanoplasmonic biosensors for multicolor visual analysis of acetylcholinesterase activity and drug inhibitor screening in point-of-care testing
Biosens Bioelectron. 2023 Dec 8;247:115912. doi: 10.1016/j.bios.2023.115912. Online ahead of print.ABSTRACTThe monitoring of acetylcholinesterase (AChE) activity and the screening of its inhibitors are significance of the diagnosis and drug therapy of nervous diseases. A metal ions-mediated signal amplification strategy was developed for the highly sensitive and multicolor assay of AChE activity and visually screening its drug inhibitors. After the specific reaction between AChE and acetylthiocholine (ATCh), the hydrolysis product thiocholine (TCh) can directly and decompose the α-FeOOH nanorods (NRs) to release amounts o...
Source: Biosensors and Bioelectronics - December 14, 2023 Category: Biotechnology Authors: De Yan Li Lu Chen Cai Yan Li Jin Zhang Yan Zhao Yun Hui Yang Tong Yang Source Type: research
Design, synthesis, and biological evaluation of novel donepezil-tacrine hybrids as multi-functional agents with low neurotoxicity against Alzheimer's disease
In this study, the target compounds were evaluated for their ability to inhibit AChE and butyrylcholinesterase (BuChE) in vitro, using tacrine (hAChE, IC50 = 305.78 nM; hBuChE, IC50 = 56.72 nM) and donepezil (hAChE, IC50 = 89.32 nM; hBuChE, IC50 = 9137.16 nM) as positive controls. Compound B19 exhibited an excellent and balanced inhibitory potency against AChE (IC50 = 30.68 nM) and BuChE (IC50 = 124.57 nM). The cytotoxicity assays demonstrated that the PC12 cell viability rates of compound B19 (84.37 %) were close to that of tacrine (87.73 %) and donepezil (79.71 %). Potential therapeutic effects in AD were evaluated using...
Source: Bioorganic Chemistry - December 6, 2023 Category: Chemistry Authors: Ningwei Wang Wenlong Jia Junqin Wang Zejun Yang Yaoyang Liu Dehua Huang Xiaohan Mei Xinxin Xiong Jing Shi Yadong Tang Guang Chen Donghua Di Yunlei Hou Yajing Liu Source Type: research
Design, synthesis, and biological evaluation of novel donepezil-tacrine hybrids as multi-functional agents with low neurotoxicity against Alzheimer's disease
In this study, the target compounds were evaluated for their ability to inhibit AChE and butyrylcholinesterase (BuChE) in vitro, using tacrine (hAChE, IC50 = 305.78 nM; hBuChE, IC50 = 56.72 nM) and donepezil (hAChE, IC50 = 89.32 nM; hBuChE, IC50 = 9137.16 nM) as positive controls. Compound B19 exhibited an excellent and balanced inhibitory potency against AChE (IC50 = 30.68 nM) and BuChE (IC50 = 124.57 nM). The cytotoxicity assays demonstrated that the PC12 cell viability rates of compound B19 (84.37 %) were close to that of tacrine (87.73 %) and donepezil (79.71 %). Potential therapeutic effects in AD were evaluated using...
Source: Bioorganic Chemistry - December 6, 2023 Category: Chemistry Authors: Ningwei Wang Wenlong Jia Junqin Wang Zejun Yang Yaoyang Liu Dehua Huang Xiaohan Mei Xinxin Xiong Jing Shi Yadong Tang Guang Chen Donghua Di Yunlei Hou Yajing Liu Source Type: research
Characterization of Potentially Inappropriate Medications That Need Special Attention in the Elderly with Dementia by Analyzing Pharmacy Claims Data
Biol Pharm Bull. 2023;46(12):1699-1705. doi: 10.1248/bpb.b23-00385.ABSTRACTCommunity pharmacists may play a key role in promoting deprescribing of potential inappropriate medications (PIMs) that are highly prevalent among community-dwelling elderly with dementia. To characterize PIMs categories that need a special attention for dementia patients, in the present study, we analyzed the anonymized pharmacy claims data of patients aged 65 years and older (n = 333869) who visited nationwide 905 community-based pharmacies of Sugi Pharmacy Co., Ltd. during December 1-31, 2019. A dementia group was defined as patients who received...
Source: Biological and Pharmaceutical Bulletin - December 3, 2023 Category: Drugs & Pharmacology Authors: Yoshihito Kasanami Takashi Yamamoto Tomoyoshi Miyamoto Sumio Matzno Mikio Sakakibara Masahiro Iwaki Atsufumi Kawabata Source Type: research
Characterization of Potentially Inappropriate Medications That Need Special Attention in the Elderly with Dementia by Analyzing Pharmacy Claims Data
Biol Pharm Bull. 2023;46(12):1699-1705. doi: 10.1248/bpb.b23-00385.ABSTRACTCommunity pharmacists may play a key role in promoting deprescribing of potential inappropriate medications (PIMs) that are highly prevalent among community-dwelling elderly with dementia. To characterize PIMs categories that need a special attention for dementia patients, in the present study, we analyzed the anonymized pharmacy claims data of patients aged 65 years and older (n = 333869) who visited nationwide 905 community-based pharmacies of Sugi Pharmacy Co., Ltd. during December 1-31, 2019. A dementia group was defined as patients who received...
Source: Biological and Pharmaceutical Bulletin - December 3, 2023 Category: Drugs & Pharmacology Authors: Yoshihito Kasanami Takashi Yamamoto Tomoyoshi Miyamoto Sumio Matzno Mikio Sakakibara Masahiro Iwaki Atsufumi Kawabata Source Type: research
Characterization of Potentially Inappropriate Medications That Need Special Attention in the Elderly with Dementia by Analyzing Pharmacy Claims Data
Biol Pharm Bull. 2023;46(12):1699-1705. doi: 10.1248/bpb.b23-00385.ABSTRACTCommunity pharmacists may play a key role in promoting deprescribing of potential inappropriate medications (PIMs) that are highly prevalent among community-dwelling elderly with dementia. To characterize PIMs categories that need a special attention for dementia patients, in the present study, we analyzed the anonymized pharmacy claims data of patients aged 65 years and older (n = 333869) who visited nationwide 905 community-based pharmacies of Sugi Pharmacy Co., Ltd. during December 1-31, 2019. A dementia group was defined as patients who received...
Source: Biological and Pharmaceutical Bulletin - December 3, 2023 Category: Drugs & Pharmacology Authors: Yoshihito Kasanami Takashi Yamamoto Tomoyoshi Miyamoto Sumio Matzno Mikio Sakakibara Masahiro Iwaki Atsufumi Kawabata Source Type: research
EPH75 Adverse Event Types and Discontinuation Rate of Alzheimer's Medication Approved by United States Food and Drug Administration (USFDA)
Alzheimer's Disease and related dementia (ADRD) is a public health emergency affecting the aging population in the US. By 2023, 6.7 million Americans 65 and older are estimated to have Alzheimer's. Pharmacological management of Alzheimer's includes inhibition of acetylcholinesterase and N-methyl-D-aspartate receptors. AChEIs like donepezil, galantamine, and rivastigmine treat mild and severe AD. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Almutairi, V. Sanogo, K. Diaby Source Type: research
EE655 Patients Level Cost of Treating Adverse Events in Alzheimer ’s Disease for US-FDA Approved Treatments
This study aims to calculate the patient level cost of managing AEs related to AD treatments, per treatment, treatment category, and discontinued AEs per treatment for all US FDA-approved drugs for AD as of May 31, 2023. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: V. Sanogo, R. Almutairi, K. Diaby Source Type: research
EE500 An Overview of Systematic Literature Review of Economic Evaluation of Treatment on Patients With Alzheimer's Disease and Related Dementia
Alzheimer's and related dementias are estimated to affect 6.7 million Americans aged 65+ in 2023, 73% of whom are over 75. By 2050, 12.7 million are expected to have AD. Pharmacological management includes inhibitors of acetylcholinesterase and N-methyl-D-aspartate receptors, with AChEIs such as donepezil, galantamine, and rivastigmine recommended for mild and moderate cases. In 2023, costs are estimated to be $345 billion, with Medicare and Medicaid covering $222 billion. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: V. Sanogo, R. Almutairi, K. Diaby Source Type: research
EE350 Budget Impact of Memantine for Alzheimer's Patient in the United States
6.7 million Americans 65 and older will have Alzheimer's by 2023. 73% of the population is 75 years or older. The projected frequency of AD worldwide in 2050 is 12.7 million. Acetylcholinesterase inhibitors (AChEIs) including donepezil, galantamine, and rivastigmine are used to treat mild and severe AD. Alzheimer's and other dementias will cost the US $345 billion in 2023, of which $222 billion will come from Medicare and Medicaid. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Almutairi, V. Sanogo, K. Diaby Source Type: research
